Related Experiment Video
Updated: May 12, 2026
08:30
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
Published on: March 12, 2016
Does autoimmunity play a part in the pathogenesis of glaucoma?
Katharina Bell1, Oliver W Gramlich, Nadine Von Thun Und Hohenstein-Blaul
1Experimental Ophthalmology, Department of Ophthalmology, University Medical Center of the Johannes Gutewnberg University, Langenbeckstr. 1, 55131 Mainz, Germany.
Progress in Retinal and Eye Research
|April 2, 2013
Summary
Glaucoma autoantibodies may cause or protect against retinal damage. Understanding this balance could lead to new glaucoma diagnostics and therapies for preventing blindness.
Area of Science:
- Ophthalmology
- Neuroimmunology
- Neurodegeneration
Background:
- Glaucoma is a leading cause of blindness, characterized by neurodegeneration and risk factors like elevated intraocular pressure.
- Altered serum antibody profiles, including upregulation and downregulation of specific autoantibodies, are observed in glaucoma patients.
- The role of autoantibodies in glaucoma pathogenesis (causative vs. epiphenomenon) remains unclear.
Purpose of the Study:
- To investigate the dual role of autoantibodies in glaucoma, exploring both their potential to cause damage and offer protection.
- To examine the presence of antibody deposits and pro-inflammatory environments in human glaucomatous retinae.
- To assess the impact of glaucomatous serum on neuroretinal cell regulatory processes.
Main Methods:
- Analysis of serum antibody profiles in glaucoma patients.
- Histopathological examination of human glaucomatous retinae for antibody deposits and inflammatory markers.
- In vitro studies assessing the effects of glaucomatous serum on neuroretinal cells.
Main Results:
- Evidence of antibody deposits in human glaucomatous retinae within a pro-inflammatory environment.
- Glaucomatous serum demonstrated the potential to influence neuroretinal cell regulatory processes.
- Certain autoantibodies were found to possess neuroprotective potential for neuroretinal cells.
Conclusions:
- The complex interplay between autoaggressive and neuroprotective autoantibodies in glaucoma requires further investigation.
- Understanding these mechanisms may reveal novel therapeutic targets for glaucoma treatment.
- Altered antibody profiles show promise as sensitive and specific biomarkers for early glaucoma diagnosis and monitoring progression.
Related Concept Videos
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
01:29Autoimmune Disorders
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Concept and Mechanism of Autoimmune Diseases
The immune system...
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...